Method of treating an epstein-barr viral infection

• US 5,334,395 A
• Filed: 08/24/1992
• Issued: 08/02/1994
• Est. Priority Date: 08/04/1988
• Status: Expired due to Fees

• Current Assignee: Kremers Urban LLC
• Original Assignee: Kremers Urban LLC
• Inventors: Steinbach, Thomas, Hermann, William J. Jr., Lawyer, Carl H., Wagle, Sudhakar S., Gawish, Ali A. S.
• Primary Examiner(s): Robinson, Douglas W.
• Assistant Examiner(s): Witz, Jean C.
• Application Number:
  US07/934,554
• Time in Patent Office: 708 Days
• Field of Search: 424/553, 514/21, 514/885, 530/846
• US Class Current: 424/553
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/407 Liver; Hepatocytes
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: Y10S 530/846 Liver

Abstract

A therapeutic method for treating Epstein-Barr virus infection. The method comprises administering a therapeutically-effective amount of a mammalian liver extract, the extract being characterized by being heat stable, insoluble in acetone and soluble in water, peptide or peptide fragment selected from the groups consisting of Sequence Identification Numbers 1-9.

Claims

1. A method of treating an Epstein-Barr viral infection comprising administering to a mammal having Epstein-Barr virus infection a therapeutically effective amount of a mammalian liver extract, referred to as KU10,001, the extract being heat stable, insoluble in acetone and soluble in water.

2. The method of claim 1 wherein said Epstein-Barr viral infection is acute infectious mononucleosis.

3. The method of claim 1 wherein the liver extract is contained in a pharmaceutically-acceptable carrier at a concentration of about 2.5% by weight solids.

4. The method of claim 3 wherein the liver extract is contained in water.